Chalcogen Bonded Directly To Ring Carbon Of The Six-membered Hetero Ring Patents (Class 514/345)
  • Patent number: 10278969
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventor: Suzie Ribeiro
  • Patent number: 10188637
    Abstract: The disclosure relates to granulate formulations of pirfenidone and methods of making such formulations.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 29, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventor: Siddharthya Krishnachandan Mujumdar
  • Patent number: 10004736
    Abstract: The present invention relates to methods of preventing or treating skin necroptosis diseases, including administering to subjects receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blockers or dabrafenib, and method of diagnosing of skin necroptosis diseases, including detecting phosphorylated MLKL. The RIP3-MLKL pathway blockers according to the present invention directly suppress RIP3 overexpressing in skin necroptosis diseases, or inhibit phosphorylation and translocation to plasma membranes of MLKL, subsequently induced therefrom, thereby effectively preventing skin cell death via necroptosis. Thus, the present invention can prevent or treat a variety of skin diseases caused by necroptosis.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 26, 2018
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventor: You Sun Kim
  • Patent number: 9925282
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy Shoup
  • Patent number: 9894894
    Abstract: The invention provides, in various embodiments, systems, devices and methods relating to ex-vivo organ care. In certain embodiments, the invention relates to maintaining an organ ex-vivo at near-physiologic conditions. The present application describes a method for using lactate measurement in the arterial and the venous blood lines of the Organ Care System Heart perfusion device to evaluate the: 1) The overall perfusion status of an isolated heart and 2) The metabolic status of an isolated heart and 3) the overall vascular patency of an isolated donor heart. This aspect of the present invention uses the property of myocardial cell's unique ability to produce/generate lactate when they are starved for oxygen and metabolize/utilize lactate for energy production when they are well perfused with oxygen.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: February 20, 2018
    Assignee: TRANSMEDICS, INC.
    Inventors: Waleed Hassanein, Tamer Khayal, Ahmed Elbetanony, Paul Lezberg, Giovanni Cecere, Dennis Sousa, Elizabeth Hansen
  • Patent number: 9890112
    Abstract: The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: February 13, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Romain Najman, Florence Mahuteau, Pierre Roux
  • Patent number: 9663442
    Abstract: Disclosed is the use of benzotropolone derivatives of formula wherein R1, R2 and R7 independently from each other are hydrogen; C1-C3alkyl; or COR8; R3 is hydrogen; or COOR9 R4 is hydrogen; or C1-C3alkyl; R5 is hydrogen; hydroxy; C1-C3-alkoxy; or —O—(CO)—R10; R6 is hydrogen; C1-C3alkyl; or COR8; or R5 and R6 together may form a five or six membered ring; or R6 and R7 together form a five or six membered ring; and R8, R9, R10 independently of each other are C1-C30alkyl; for protecting body-care and household products from photolytic and oxidative degradation.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: May 30, 2017
    Assignee: BASF SE
    Inventors: Barbara Winkler, Oliver Reich, Alexander Mantler, Reinhold Ohrlein, Walter Fischer, Albert Schneider
  • Patent number: 9566342
    Abstract: A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: February 14, 2017
    Assignee: SOLVOTRIN INNOVATIONS LIMITED
    Inventors: John Gilmer, Mark Ledwidge, Ken McDonald, Pat O'Flynn
  • Patent number: 9562053
    Abstract: The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: February 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Nalin Subasinghe
  • Patent number: 9549942
    Abstract: The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: January 24, 2017
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: Dong Gyu Jo, Jong Sung Park, Youngkwang Youn, Yuri Choi, Ui Jeong Yun
  • Patent number: 9526703
    Abstract: A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: December 27, 2016
    Assignee: Duchesnay Inc.
    Inventors: Manon Vranderick, Jean-Luc St-Onge, Michele Gallo, Éric Gervais
  • Patent number: 9517993
    Abstract: Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: December 13, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Hang Yin, Kui Cheng
  • Patent number: 9504677
    Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 29, 2016
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas G. Gant, Sepehr Sarshar
  • Patent number: 9422248
    Abstract: A substituted phenol compound represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof. At least one of X and Y is CH, and the other one of X and Y is N or CH. R1 is C1-C4 alkyl or C1-C4 haloalkyl. R2 is C1-C4 alkyl, or halogen. R3 is H, C1-C4 alkyl, aryl, or —(CH2)n-aryl, in which n is 1, 2, or 3. The compound is useful as anticonvulsant.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: August 23, 2016
    Assignee: University of Iowa Research Foundation
    Inventors: Max T. Baker, Rajesh K. Mishra
  • Patent number: 9381245
    Abstract: The invention provides methods and compositions for reducing or inhibiting osteolysis, bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that inhibits the biological activity of an axon guidance protein. The compound or agent my inhibit transcription or translation of or bind to an axon guidance protein, such as, for instance, a netrin like netrin-1. Likewise, the compound or agent may inhibit transcription or translation of or bind to a receptor of an axon guidance protein, such as, for instance, a netrin receptor such as unc5b. In some instances, the compound or agent is an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such compounds and agents.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: July 5, 2016
    Assignee: New York University
    Inventors: Bruce N Cronstein, Kathryn J Moore, Aranzazu Mediero-Munoz, Bhama Ramkhelawon
  • Patent number: 9370181
    Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more carbamate compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of alanycarb, aldicarb, aldoxycarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb, ethiofencarb, fenobucarb, fenothiocarb, fenoxycarb, furathiocarb, isoprocarb, metolcarb, methomyl, methiocarb, oxamyl, pirimicarb, propoxur, XMC, thiodicarb and xylylcarb.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: June 21, 2016
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: So Kiguchi, Soichi Tanaka
  • Patent number: 9334256
    Abstract: This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 10, 2016
    Assignee: NoNO INC.
    Inventors: Xiujun Sun, Michael Tymianski
  • Patent number: 9288996
    Abstract: The present invention relates to a composition, comprising a microorganism of species Penicillium bilaji and at least one compound (II) in a synergistically effective amount.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: March 22, 2016
    Assignee: BASF SE
    Inventors: Thorsten Jabs, Paul Cavell, Sarah Dunker, Alexander Wissemeier, Egon Haden, Tom Wetjen
  • Patent number: 9289401
    Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 .mu.g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 22, 2016
    Inventor: Darlene E. McCord
  • Patent number: 9247733
    Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 2, 2016
    Assignee: The Hartz Mountain Corporation
    Inventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
  • Patent number: 9212135
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: December 15, 2015
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Jean-Michel Vernier, Esmir Gunic
  • Patent number: 9185911
    Abstract: The present invention is to provide a composition for preventing plant diseases which comprises at least Component I and Component II, is capable of obtaining a synergic effect that cannot be expected with each single component, is capable of markedly increasing a control effect in a much smaller amount of chemicals against various plant pathogens, and causes no phytotoxicity suffering. A composition for preventing plant diseases comprises Components I and II as active ingredients. The Component I is (RS)—N-[2-(1,3-dimethylbutyl)thiophen-3-yl]-1-methyl-3-tri fluoromethyl-1H-pyrazole-4-carboxamide.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: November 17, 2015
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Syunichi Inami, Yuji Yanase
  • Patent number: 9151759
    Abstract: The subject matter disclosed in this specification pertains to a method for detecting cells with elastic cell membranes. A plurality of cells are fixed to an impedimetric transducer and osmotic stress is applied. Those cells with elastic membranes, including cancer cells, undergo a volume change which is detected by the impedimetric transducer.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: October 6, 2015
    Assignee: Research Foundation of the City University of New York
    Inventors: Hiroshi Matsui, Roberto de la Rica, Menglu Shi
  • Patent number: 9049860
    Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: June 9, 2015
    Assignee: The Hartz Mountain Corporation
    Inventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
  • Publication number: 20150148382
    Abstract: The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial/antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 28, 2015
    Inventors: Juan Socorro Armendáriz Borunda, José Agustín Rogelio Magaña Castro, Pedro Peña Santoyo, Laura Vàzquez Cervantes
  • Patent number: 9040082
    Abstract: Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 26, 2015
    Inventor: Jon D. Kaiser
  • Publication number: 20150141466
    Abstract: The invention relates to a composition which contains at least one N-acyl-amino acid surfactant, a betaine surfactant, an N-methyl-N-acylglucamine, said N-methyl-N-acylglucamine having a C16-C20-acyl group, and further contains a solvent and optionally one or more additives. The invention also relates to a method for producing the composition. The invention further relates to the use of the composition for the treatment or care of skin or hair, or for use as a shampoo, face cleaner, liquid cleaner or shower gel.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 21, 2015
    Inventors: Peter Klug, Carina Mildner
  • Patent number: 9034943
    Abstract: The invention provides a method for preventing discoloration of pyrithione-containing materials, in particular plastic materials or other material such as paints, coatings, adhesives or textiles which are exposed to an outdoor environment. The method is likewise suited for preventing discoloration of other pyrithione-containing materials such as personal care compositions like shampoos. A discoloration inhibitor that includes dehydroacetic acid or a salt thereof is added to the pyrithione-containing material. The discoloration is prevented without the addition of a cyclic organic phosphoric acid ester or an organic phosphite. Use of the discoloration inhibitor does not interfere with the antimicrobial effect of the pyrithione.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 19, 2015
    Assignee: LONZA LTD
    Inventors: Larry Kent Hall, Joseph Kimler, Lei Rao
  • Publication number: 20150132410
    Abstract: The invention provides compositions for the prevention and treatment of the symptoms of alcoholic beverage-induced hangover syndrome, related kits and methods of using the compositions and kits.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventor: Michael M. Jacobs
  • Publication number: 20150133378
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Patent number: 9028854
    Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether; a hydrophobic organic solvent capable of dissolving 0.1-fold by weight of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether at 0° C.; polyvinyl alcohol; a nonionic surfactant selected from the group consisting of alkoxylated castor oil, alkoxylated hydrogenated castor oil and alkoxylated hydrogenated castor oil fatty acid ester; and water, is excellent in storage stability.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: May 12, 2015
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Toshiyuki Tanedani
  • Patent number: 9029322
    Abstract: The present invention relates to a method for identifying a drug candidate for enhancing expression of p21cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21C?1/waf1. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21cip1/waf1 promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cip1/waf1.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 12, 2015
    Assignee: Cornell University
    Inventors: Rajiv R. Ratan, Brett C. Langley, Brian S. Ko
  • Patent number: 9028878
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 12, 2015
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Publication number: 20150126436
    Abstract: The present invention provides a method of treatment of Scedosporium spp.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 7, 2015
    Applicant: BIODIEM LIMITED
    Inventors: Julie Phillips, Tania Sorrell, Sharon Chen
  • Publication number: 20150126562
    Abstract: Disclosed herein are methods of administering deuterated pirfenidone and kits thereof.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventor: Chengzhi Zhang
  • Publication number: 20150111860
    Abstract: The present invention relates to a suspoemulsion comprising the following ingredients (1), (2), (3), (4), (5), and (6): an ingredient (1): low water-soluble liquid pesticidal ingredient, an ingredient (2): low water-soluble pesticidal active ingredient which is solid at normal temperature, an ingredient (3): polyoxyalkylene block copolymer, an ingredient (4): phosphate ester salt and/or sulfate ester salt of polyoxyethylene aryl phenyl ether, an ingredient (5): ligninsulfonic acid salt, and an ingredient (6): water. The suspoemulsion of the present invention is a formulation having excellent storage stability, which suppresses the particle growth of dispersoids of an ingredient (1) and an ingredient (2) during storage at high temperature and low temperature, and causes neither aggregation nor separation of dispersoids, nor formation of a hard cake, nor a change in appearance.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 23, 2015
    Inventor: Takuya Tanaka
  • Publication number: 20150111885
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Michael John Bennett, Juan Manuel Betancort, Amogh Boloor, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Publication number: 20150111899
    Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Williamson Z. Bradford, Javier Szwarcberg
  • Patent number: 9012494
    Abstract: The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; L represents a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4alkyl, C1-3alkyloxy-C1-4alkyl-, hydroxy-C1-4alkyl, hydroxy, C1-3alkyloxy- or phenyl-C1-4alkyl; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from hydroxy, C1-4alkyl or C1-4alkyloxy; R1 and R2 each independently represent hydrogen, halo, cyano, hydroxy, C1-4alkyl optionally substituted with halo, C1-4alkyloxy- optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar1 and halo; or R1 and R2 taken together with the phenyl ring to which they are attached form naphtyl or 1,3-benzodioxolyl, wherein said naphtyl or 1,3-benzodioxolyl are optionally substituted with halo; R3 represents hydrogen, halo, C1-4alkyl, C1-4alkyloxy-, cyano or hydroxy; R4 represents hydrogen, halo,
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: April 21, 2015
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Libuse Jaroskova, Joannes Theodorus Maria Linders, Christophe Francis Robert Nestor Buyck, Louis Jozef Elisabeth Van Der Veken, Vladimir Dimtchev Dimitrov, Theo Teofanov Nikiforov
  • Patent number: 9000013
    Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 7, 2015
    Inventor: Alfred A. Nickel
  • Patent number: 9000177
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: April 7, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
  • Publication number: 20150093458
    Abstract: A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6. Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.
    Type: Application
    Filed: September 27, 2014
    Publication date: April 2, 2015
    Inventor: Justin SHER
  • Publication number: 20150087679
    Abstract: Embodiments of the present invention relate to a nutritional sleep supplement having a balanced ratio of nutritional elements to facilitate a healthy lifestyle. In one embodiment, a nutritional sleep supplement has a set of active ingredients, the active ingredients comprising: between 50 mg to 600 mg of 5-Hydroxytryptophan; between 125 mg to 1500 mg of calcium lactate; between 50 mg to 600 mg of citric acid; between 125 mg to 1500 mg of gamma-Aminobutyric acid; between 50 mg to 600 mg of L-theanine; between 25 mg to 300 mg of L-tryptophan; between 45 mg to 540 mg of magnesium glycinate; between 1.25 mg to 15 mg of melatonin; between 8.75 mg to 105 mg of niacin; between 7.5 mg to 90 mg of potassium sorbate; and between 10 mg to 100 mg of pyridoxine.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Hany HELMI, Andrew PANDYA
  • Publication number: 20150071874
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20150073023
    Abstract: The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders
    Type: Application
    Filed: September 26, 2013
    Publication date: March 12, 2015
    Inventors: Yaron Daniely, Dalia Megiddo
  • Patent number: 8969576
    Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 3, 2015
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas G. Gant, Sepehr Sarshar
  • Patent number: 8969390
    Abstract: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: March 3, 2015
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Peter Klug, Sonja Gehm, Guiseppina Kluth, Franz-Xaver Scherl, Maurice Frederic Pilz
  • Patent number: 8969347
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: March 3, 2015
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
  • Patent number: 8969575
    Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 3, 2015
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Thomas G. Gant, Sepehr Sarshar
  • Patent number: 8962661
    Abstract: To provide a fungicidal composition having stable and high fungicidal effects against cultivated crops infected with plant diseases resulting from plant diseases. A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the formula (I) or its salt: wherein when A is —N?, B is —CX4?; when A is —CH?, B is —N?; each of X1 and X2 which are independent of each other, is a halogen atom, an alkoxy group, a hydroxyl group, an alkyl group, a CF3 group or an alkylthio group; X3 is a hydrogen atom, a halogen atom, an alkoxy group, an alkyl group, a CF3 group or an alkylthio group; X4 is a hydrogen atom, a halogen atom, an alkoxy group, an alkyl group, a CF3 group or an alkylthio group; R1 is an alkyl group; R2? is an alkoxy group; p is 0, 1 or 2; and each of R2? and R2?? is an alkoxy group, and (b) at least one additional fungicide.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 24, 2015
    Assignee: Ishihara Sangyo Kaisha, Ltd.
    Inventors: Munekazu Ogawa, Akihiro Nishimura